netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Renewed Hope for Gene Therapy to Restore Vision

A few years ago, in a major milestone, RPB-supported researchers used gene therapy to restore partial sight in patients with Lebers Congenital Amaurosis, a form of retinitis pigmentosa. For a while, their sight improved. But, earlier this year, reports indicated that the treatment's effects were wearing off, and that the patients' sight was again diminishing as the degeneration of their photoreceptor cells progressed.

One proposed explanation for the ongoing degeneration was that the disease had already reached a point of no return when the initial gene therapy had been applied; the photoreceptors were already beyond permanent rescue.

Now, new findings from the lab of RPB researcher Stephen H. Tsang, MD, PhD, Columbia University College of Physicians & Surgeons, are rekindling hope for the use of gene therapy to restore vision in patients with retinal degenerative conditions.

"Our report is the first to demonstrate a stable halting of a retinal degeneration," says Tsang. "It also demonstrates a relatively broad therapeutic time window for a preclinical retinitis pigmentosa (RP) model."

The Tsang team found that, if the gene therapy was optimally delivered, it could be effective at any time during the course of the disease.

"Our study points to non-optimal delivery of the gene therapeutic as a cause of continued degeneration, and suggests that the way forward for developing RP therapeutics is to focus on optimizing delivery, which we have demonstrated in a model. Our work also speaks to the need for earlier precision medicine diagnosis, so these gene therapeutics can freeze the degeneration cascade earlier in the disease course." (Read a Profile on RPB Physician-Scientist Tsang, his work on precision diagnosis, and the influence that RPB Grants have had on his career.)

According to Tsang, the results of this project will allow gene therapists to better counsel their patients on prognosis, alert them to critical periods for treatment and assess the efficacy of future therapeutic approaches.

Most important to patients, these findings suggest that RP can be treated despite being diagnosed after the disease has compromised many cells.

Related News: Drug Delivery, Feature Story, Gene Therapy, Retinitis Pigmentosa, Top Story

Dr. Alex Huang

Research to Prevent Blindness and Alcon Award Glaucoma Grant

Dr. Alex Huang of the University of California San Diego School of Medicine will study glaucoma filtration surgeries with the aim of improving surgical success for lowering eye pressure and providing neuroprotection.

Read More

 
clock icon

Researchers Build An “Aging Clock” To Help Treat Eye Disease

The new way to measure ocular aging opens treatment avenues for numerous eye diseases.

Read More

 
RPB Logo

Research to Prevent Blindness and the American Academy of Ophthalmology Award Big Data Research Grants for Improved Patient Care

The American Academy of Ophthalmology (AAO) and Research to Prevent Blindness (RPB) today announced the 2023 recipients of the RPB/AAO Award for IRIS Registry Research.

Read More

 
RPB logo

In Memoriam: Herbert J. Siegel

RPB acknowledges the passing of a dedicated former Board member.

Read More

 
Patricia D'Amore, PhD

Research to Prevent Blindness and Association of University Professors of Ophthalmology Announce 2024 Recipient of RPB David F. Weeks Award for Outstanding Vision Research

Patricia Ann D’Amore, PhD, MBA, is recognized for ground-breaking contributions to the field of vision research.

Read More

 
Dr. Akrit Sodhi

RPB-Supported Researcher Makes Progress on Diabetic Retinopathy Treatment

Dr. Akrit Sodhi at Johns Hopkins Medicine has published a new study showing promise for an experimental treatment to prevent or slow vision loss in people with diabetes.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.